Heart failure and tachycardiomyopathy in a patient taking ibrutinib: a novel tyrosine kinase inhibitor.

被引：0

作者：

Codina, M. ^{[1
]}

Ramirez-Escudero, G. ^{[2
]}

Garcia Ibarrondo, N. ^{[2
]}

Manzanal Rey, A. ^{[2
]}

Bravo Martinez, I. ^{[3
]}

Aurrekoetxea Bajeneta, G. ^{[3
]}

Mendoza Cuartero, P. ^{[3
]}

Asla Ormaza, C. ^{[3
]}

Castellano Alcalde, M. ^{[3
]}

Uriarte Elguezabal, J. A. ^{[4
]}

Marquez Navarro, J. A. ^{[4
]}

De Bourio Uriarte, R. Martinez ^{[5
]}

Arregui Lopez, A. ^{[6
]}

Arcocha Torres, M. F. ^{[7
]}

Ruiz Gomez, L. ^{[2
]}

机构：

[1] Hosp Basurto, Noninvas Cardiac Imaging Lab, Cardiooncol, Bilbao, Spain

[2] Hosp Basurto, Noninvas Cardiac Imaging Lab, Bilbao, Spain

[3] Hosp Basurto, Dept Cardiol, Bilbao, Spain

[4] Hosp Basurto, Dept Hematol, Bilbao, Spain

[5] Hosp Basurto, Cardiac Catheterizat Lab, Bilbao, Spain

[6] Hosp Basurto, Cardiol Intens Care Unit, Bilbao, Spain

[7] Hosp Basurto, Dept Cardiol, Electrophysiol Lab, Bilbao, Spain

来源：

EUROPEAN JOURNAL OF HEART FAILURE | 2019年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P1210

引用

页码：303 / 303

页数：1

共 50 条

[31] The Promising Impact of Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, for the Management of Lymphoid Malignancies
Bhatt, Valkal
Alejandro, Linh
Michael, Angela
Ganetsky, Alex
PHARMACOTHERAPY, 2014, 34 (03): : 303 - 314
[32] The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae
Wang, Kun
Xu, Qiushi
Zhong, Hanbing
FRONTIERS IN PHARMACOLOGY, 2021, 11
[33] ACCLERATED HYPERTENSION IN A PATIENT ON AXITINIB - A TYROSINE KINASE INHIBITOR
Aslam, Ahsan
Gupta, Nupur
Safdar, Faryal
AMERICAN JOURNAL OF KIDNEY DISEASES, 2022, 79 (04) : S21 - S21
[34] Phase I study of SU014813, a novel oral multi-targeted receptor tyrosine kinase (RTK) inhibitor.
Fiedler, W
Giaccone, G
Lasch, P
Van der Horst, I
Brega, NM
Gentile, A
Ljubimir, V
Pithavala, YK
Bokemeyer, C
Boven, E
CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9061S - 9061S
[35] Pleural and pericardial effusions in patient on tyrosine kinase inhibitor
Pysyk, Christopher L.
Asmis, Tim
Gilbert, Sebastien
JOURNAL OF CLINICAL ANESTHESIA, 2018, 45 : 20 - 21
[36] IGFBP-7 to confer resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.
Wu, Shang-Gin
Chang, Tzu-Hua
Chang, Yih-Leong
Tsai, Meng-Feng
Yu, Chong-Jen
Shih, Jin-Yuan
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[37] Reduction of CD34+ Philadelphia (Ph) chromosome positive cells with a tyrosine kinase inhibitor.
Heinzinger, M
Ali, M
Waller, CF
Rosenstiel, A
Mertelsmann, R
Lange, W
BLOOD, 1997, 90 (10) : 3994 - 3994
[38] Tyrosine kinase-inhibitors and heart failure risk
Das, Manjulika
LANCET ONCOLOGY, 2017, 18 (06): : E302 - E302
[39] Heart failure with tyrosine kinase-targeting drugs
Reactions Weekly, 2017, 1649 (1) : 10 - 10
[40] Reversal of tumorigenic phenotype of BCR-ABL-expressing cells resistant to a tyrosine kinase inhibitor by the use of a proteasome inhibitor.
Deutsch, E
Dugray, A
Turhan, AG
Bourhis, J
BLOOD, 2001, 98 (11) : 570A - 570A

← 1 2 3 4 5 →